BCL2 and cancer: We observed 70% (n = 225) of these cancer-network proteins as being targetable by existing approved or investigational therapies, with notable examples including BCL2 and BTK. Of the remaining 97 genes, 34 are commonly essential, 11 possess concordant lineage specificity, 48 are ligandable by 3D structure and 11 have an existing high-quality probe available (Supplementary Table 13).